AIM: To evaluate the effectiveness of intravitreal bevacizumab(IVB)and ranibizumab(IVR)for the treatment of type 1 retinopathy of prematurity(ROP)by Meta-analysis.

METHODS: The PubMed, Embase, Web of Science, the Cochrane Library, CNKI, CQVIP, CBM, OVID and Wanfang were systematically searched. All comparative studies of IVB or IVR as treatment for ROP were included. Two independent reviewers performed the date extraction and assessed study quality. Meta-analysis was performed using Review Manager 5.3 software. The retreatment rate was defined as the primary outcome. Secondary outcomes were prevalence of complete vascularization and myopic(spherical equivalent, SE).

RESULTS: Eight non-randomized studies, including a total of 885 eyes were included in this study. Compared with IVB-treated children, IVR-treated children have higher retreatment rate \〖OR=0.55, 95% CI:0.34-0.88, P<0.05\〗, less spherical equivalent \〖WMD= -1.44, 95% CI: -2.28 to -0.00, P<0.05\〗, and the same percentage of complete vascularization \〖OR=2.15, 95% CI: 0.80-0.576, P>0.05\〗.

CONCLUSION: Both IVR and IVB can complete the vasculization of the retina in the treatment of type 1 ROP, but the two treatments have their own advantages. IVR has little effect on the refractive effect in children, but its effect in reducing the retreatment rate is worse than IVB.